As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. 333-294716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-1488943 (State or other jurisdiction of incorporation or organization) (Primary Standard Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sor ...

As filed with the Securities and Exchange Commission on March 27, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 27-1488943 (Primary Standard Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sorrento Valley Road, Suite 100 San Diego, CA 9212 ...

Core Insights - CollPlant Biotechnologies reported significant advancements in its regenerative and aesthetic medicine initiatives, including financial results for 2025 and updates on corporate developments [1] Financial Performance - GAAP revenues for 2025 were $2.4 million, a substantial increase from $515,000 in 2024, primarily due to a $2 million milestone payment from AbbVie [20] - GAAP gross profit for 2025 was $1.5 million, compared to a gross loss of $1.1 million in 2024 [22] - GAAP net loss for 2025 was $11.5 million, or $0.94 per share, an improvement from a net loss of $16.6 million, or $1.45 per share, in 2024 [25] Corporate Developments - The company achieved a development milestone in aesthetic medicine, triggering a $2 million payment from AbbVie [2][10] - CollPlant expanded its distribution network into North America through a partnership with a U.S.-based logistics center [8] - The company launched BioFlex, a ready-to-print rhCollagen-based kit for 3D bioprinting applications, aimed at drug discovery and tissue engineering [5][6] Product Innovations - CollPlant's rhCollagen platform was utilized to create a fully humanized 3D bioprinted skin model at Mayo Clinic, providing an alternative to animal testing [4][7] - The company refined its regenerative breast implants based on new preclinical data, showing promising outcomes in tissue integration and vascularization [11][13] Intellectual Property - CollPlant secured U.S. Patent No. 12,186,449 for its photocurable dermal filler product candidate, expected to remain in force until 2039 [14] - The company received patent allowances in South Korea and Japan for its photocurable dermal filler technology and rhCollagen-based BioInks, respectively [15][16] Cost Management - CollPlant implemented a cost-reduction plan, resulting in a 25% reduction in workforce and a decrease in operating expenses from $16.1 million in 2024 to $13.0 million in 2025 [19][23]

Core Viewpoint - CollPlant Biotechnologies has launched a redesigned corporate website aimed at enhancing transparency and accessibility for investors and stakeholders, reflecting the company's advancements in regenerative medicine and aesthetics [2][4]. Company Overview - CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, utilizing its proprietary plant-derived recombinant human collagen (rhCollagen) technology [4]. - The company addresses various indications in tissue repair, aesthetics, and organ manufacturing, marking a new era in regenerative and aesthetic medicine [4]. Website Features - The new website includes expanded sections on the company's technology platform, product pipeline, strategic collaborations, and corporate governance [2][7]. - It serves as a central source of information regarding CollPlant's scientific platform, clinical and preclinical programs, and corporate updates [2][7]. Strategic Collaborations - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, which is a leader in the dermal filler market [5].

Core Insights - CollPlant Biotechnologies reported financial results for Q3 2025, showing significant growth in revenue and advancements in its product development pipeline [1][15][24]. Financial Performance - GAAP revenues for Q3 2025 were $77,000, up from $4,000 in Q3 2024, primarily due to increased sales of rhCollagen-based products [15]. - For the nine months ended September 30, 2025, GAAP revenues reached $2.3 million compared to $351,000 for the same period in 2024 [16]. - The company reported a GAAP net loss of $3.5 million for Q3 2025, an improvement from a net loss of $4.3 million in Q3 2024 [24]. Product Development and Innovation - CollPlant is advancing its dermal filler program and has achieved a key milestone in collaboration with AbbVie, receiving a $2 million payment [3][17]. - The company’s rhCollagen-based bioink, Collink.3D™, has shown superior performance compared to Matrigel® in supporting structured tissue formation, indicating a potential market opportunity of approximately $100 million with an annual growth rate of over 10% [2][15]. - A fully humanized bioprinted skin model developed at Mayo Clinic using rhCollagen offers an ethical alternative to animal testing, broadening the application of CollPlant's technology in medical and pharmaceutical research [2][16]. Strategic Initiatives - CollPlant has initiated a cost reduction plan, including a workforce reduction of approximately 25%, to extend its cash runway [5][21]. - The company is expanding its distribution capabilities in North America through a new logistics partnership, enhancing support for its rhCollagen and BioInk product lines [7][12]. - Plans are in place to actively seek a strategic partner for the continued development of its novel regenerative breast implant product candidate [6]. Market Expansion - CollPlant has expanded its international distribution network for its tendon-repair product, Vergenix™ STR, entering seven new markets in 2025, with plans for further expansion in Europe and Asia in 2026 [13][14]. - The company appointed Bowman Bagley as Vice President, Commercial North America, to lead its commercial strategy and execution across the region [16]. Balance Sheet and Cash Flow - As of September 30, 2025, cash and cash equivalents were $8.5 million, with cash used in operating activities amounting to $6.5 million for the nine months ended September 30, 2025 [26]. - The company reported a decrease in cash used in investing activities to $12,000 from $481,000 in the same period of 2024, primarily due to reduced purchases of property and equipment [27].

Company Overview - CollPlant Biotechnologies is a regenerative and aesthetics medicine company focused on developing innovative technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics [1][2] - The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, utilizing proprietary plant-based genetic engineering technology to produce rhCollagen [2] Financial Reporting - CollPlant will report its financial results for the third quarter of 2025 on November 26, 2025, before the opening of U.S. financial markets [1] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie and a leader in the dermal filler market [3]

Core Viewpoint - CollPlant Biotechnologies has announced the development of the first fully humanized 3D bioprinted skin model using its proprietary plant-derived recombinant human collagen (rhCollagen), which offers a sustainable alternative to animal testing for preclinical research and has broad applications in cosmetic and pharmaceutical testing, disease modeling, and drug development [1][7]. Group 1: Technology and Innovation - The 3D bioprinted skin model integrates CollPlant's rhCollagen-based bioinks with essential human skin cell types, enabling the evaluation of drug delivery in a non-animal model [2][7]. - The use of plant-derived rhCollagen allows for high-throughput production of personalized human skin models, which can be applied in regenerative medicine and other medical fields [2][3]. Group 2: Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing 3D bioprinting technologies for tissue repair and medical aesthetics, with products based on its proprietary rhCollagen [4]. - The company has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers, indicating its strategic partnerships in the market [5]. Group 3: Market Implications - The innovative skin model represents a significant advancement in reducing animal testing and enhancing the ethical standards of preclinical research, which could lead to broader acceptance and application in the cosmetic and pharmaceutical industries [1][7]. - The results from Mayo Clinic's research validate the potential of rhCollagen-based bioinks for various applications, including in vitro 3D models and regenerative medicine [3].

Company Overview - CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing technologies and products based on non-animal-derived recombinant human collagen (rhCollagen) [1][5] - The company aims to innovate in the fields of tissue repair, medical aesthetics, and organ manufacturing through its proprietary plant-based genetic engineering technology [5] Conference Participation - CollPlant will participate in the International Conference on Biofabrication 2025, scheduled for September 14–17, 2025, in Warsaw, Poland [1] - The company will have two presentations during the conference, showcasing its rhCollagen platform and biofabrication applications [2][7] Biofabrication and 3D Bioprinting - The conference will focus on advancements in biofabrication and bioprinting, which are crucial for medical research and the fabrication of complex scaffolds for tissue and organ engineering [2][4] - CollPlant's rhCollagen-based bioinks are highlighted for their controlled rheology, non-animal safety profile, biocompatibility, and tunable mechanical properties, making them suitable for high-fidelity 3D bioprinting [2] International Society for Biofabrication - The International Society for Biofabrication (ISBF) is a non-profit organization that promotes research and development in biofabrication, including 3D printing of tissues and regenerative medicine [3] - The ISBF organizes the annual International Conference on Biofabrication, which has grown to attract over 500 participants from various countries since its inception in 2006 [4]

Core Insights - CollPlant Biotechnologies is advancing its photocurable dermal filler program and has made significant progress in preclinical testing, preparing for clinical trials [3][4][5] - The company raised $3.6 million in a registered direct offering in the second quarter of 2025, providing financial flexibility for ongoing initiatives [17][19] - CollPlant's regenerative breast implant program aims to address a multi-billion-dollar market, focusing on safety and durability compared to existing solutions [8][10][12] Financial Performance - GAAP revenues for Q2 2025 were $179,000, a decrease from $249,000 in Q2 2024, primarily due to reduced sales of rhCollagen-based products [21] - For the first half of 2025, GAAP revenues increased to $2.2 million from $347,000 in the same period of 2024, largely due to a $2 million milestone payment from AbbVie [22][23] - GAAP net loss for Q2 2025 was $3.3 million, or $0.28 per share, an improvement from a net loss of $4.2 million, or $0.37 per share, in Q2 2024 [31] Product Development and Collaborations - The photocurable dermal filler is designed for superior skin lifting and rejuvenation, generating interest from leading medical aesthetics companies [3][4] - CollPlant has a collaboration with AbbVie, which includes a worldwide exclusive license for combining rhCollagen technology with AbbVie's products for dermal fillers [6][7] - The company is also expanding its international distribution network for its Vergenix™ STR tendon-repair product, which has received CE Mark approval and is marketed primarily in Europe [13][15] Market Position and Strategy - CollPlant's regenerative breast implants are positioned to be first-to-market with a solution that promotes natural tissue regeneration and avoids immune rejection [10][12] - The company is focusing on non-animal-derived collagen solutions, aligning with industry trends towards more sustainable and ethical medical products [20] - The appointment of a new Vice President for Commercial North America aims to enhance the company's market presence and commercial strategy in key regions [19]

Company Overview - CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [2] - The company's products are based on rhCollagen (recombinant human collagen) produced using proprietary plant-based genetic engineering technology [2] Recent Developments - CollPlant will report its financial results for the second quarter on August 20, 2025, before the opening of U.S. financial markets [1] - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market [3]